Effects of Cangfudaotan Tang on Expression of Organic Anion Transporting Polypeptide (oatp2b1) in Liver and Kidney Tissues of Rats with Phlegm Dampness Type Polycystic Ovary Syndrome (PCOS)
Objective: To explore the effect
of Cangfudaotan Tang on phlegm dampness type of PCOS and the role of oatp2b1 in
transportation and transformation of phlegm dampness. Methods: 36 SD female
rats were randomly divided into three groups: blank control group, model group
and Cangfudaotan Tang group, 12 cases in each one. After PCOS rat models were
made, rats of Cangfudaotan Tang group were treated with Cangfudaotan Tang (1.42
g/kg/d) by intragastric administration for 14 days; blank control and model
group were given with isodose saline. The expression of oatp2b1 mRNA/Protein in
liver and kidney tissues was measured and the level of testosterone (T), follicle
stimulating hormone(FSH), estradiol (E2), luteinizing hormone(LH), Serum
total cholesterol (TG), Triacylglycerols (TC), high density lipoprotein
cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) were
detected at the same time. Results: Compared with blank control group, the
expression of oatp2b1 mRNA and the level of TC, TG, LDL, LH, FSH, T in model
group were significantly increased (P < 0. 05), while the level of HDL was
significantly decreased (P < 0. 05); compared with model group, the
expression of oatp2b1 mRNA and the level of TC, TG, LDL in Cangfudaotan Tang
group were significantly lowered (P < 0.05); the level of HDL was
significantly higher; the oatp2b1 protein in kidney and liver tissues had
different degrees of expression, while there was no statistical significance
among the three groups. Conclusions: Oatp2b1 might be one of the material bases
participating in transportation and transformation of phlegmy dampness. The
mechanism of Cangfudaotan Tang treating phlegm dampness type of PCOS may be
achieved by regulating the expression of oatp2b1.
References
[1]
Zair, Z.M., Eloranta, J.J., Stieger, B., et al. (2008) Pharmacogenetics of OATP (SLC21/ SLCO) OAT and OC (SLC22) and PEPY (SLC15) Transporters in the Intestine, Liver and Kidney. Pharmacogenomics, 9, 597-624.
https://doi.org/10.2217/14622416.9.5.597
[2]
Zeng, L., Zhao, H.Y. and Luo, S.P. (2010) The Study of Improving rat Polycystic Ovarian Syndrome-Insulin Resistance (PCOS-IR) Model. CJTCMP, 5, 2341-2345.
[3]
Tan, Z.H., Li, X.J., Wu, J., et al. (2008) Study on Phlegm Dampness Syndrome in TCM with Impaired Glucose Regulation. Journal of Bright Chinese Medicine, 23, 893-895.
[4]
Liu, T., Xu, Q.L., Yang, S.Y., et al. (2009) Establishment and Evaluation of Animal Model of Phlegm Dampness Syndrome Induced by High Fat Diet. Journal of Changchun University of Traditional Chinese Medicine, 25, 333-334.
[5]
Tian, J.Z., Wang, Y.Y., Xu, Y., et al. (2006) The Types, Evaluation and Research of Animal Model of Blood Stasis Syndrome. Journal of Beijing University of Traditional Chinese Medicine, 29, 396-400.
[6]
Sarr, F.S., André, C. and Guillaume, Y.C. (2010) A Novel Biochromatographic Oatp2 Column to Study the Transmembrane Transport of Statins. Journal of Pharmaceutical and Biomedical Analysis, 52, 93-98. https://doi.org/10.1016/j.jpba.2009.11.029
[7]
Hagenbuch, B. and Gui, C. (2008) Xenobiotic Transporters of the Human Organic Anion Transporting Polypeptides (OATP) Family. Xenobiotica, 38, 778-801.
https://doi.org/10.1080/00498250801986951
[8]
Wojtal, K.A., Eloranta, J.J., Hruz, P., Gutmann, H., Drewe, J., Staumann, A., Beglinger, C., Fried, M., Kullak-Ublic, G.A. and Vavricka, S.R. (2009) Changes in mRNA Expression Levels of Solute Carrier Transporters in Inflammatory Bowel Disease Patients. Drug Metabolism and Disposition, 37, 1871-1877. https://doi.org/10.1124/dmd.109.027367
[9]
Noé, J., Portmann, R., Brun, M.E., et al. (2007) Substrate-Dependent Drug-Drug Interactions between Gemfibrozilfluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1 and OATP1B3. Drug Metabolism and Disposition, 35, 1308-1314. https://doi.org/10.1124/dmd.106.012930
[10]
Kalliokoski, A. and Niemi, M. (2009) Impact of OATP Transporters on Pharmacokinetics. British Journal of Pharmacology, 15, 693-705.
https://doi.org/10.1111/j.1476-5381.2009.00430.x
[11]
Hagenbuch, B. and Gui, C. (2008) Xenobiotic Transporters of the Human Organic Anion Transporting Polypeptides (OATP) Family. Xenobiotica, 38, 778-801.
[12]
Konig, J., Seithel, A., Gradhand, U. and Fromm, M.F. (2006) Pharmacogenomics of Human OATP Transporters. Naunyn-Schmiedeberg’s Archives of Pharmacology, 372, 432-443.
https://doi.org/10.1007/s00210-006-0040-y
[13]
Wojtal, K.A., Eloranta, J.J., Hruz, P., Gutmann, H., Drewe, J., Staumann, A., Beglinger, C., Fried, M., Kullak-Ublick, G.A. and Vavricka, S.R. (2009) Changes in mRNA Expression Levels of Solute Carrier Transporters in Inflammatory Bowel Disease Patients. Drug Metabolism and Disposition, 37, 1871-1877. https://doi.org/10.1124/dmd.109.027367
[14]
Sai, Y., Kaneko, Y., Ito, S., et al. (2006) Predominant Contribution of Organic Anion Transport in Polypeptide oatp2b1 to Apical Uptake of Estrone-3-Sulfate by Human Intestinal Caco-2 Cells. Drug Metabolism and Disposition, 34, 1423-1431.
https://doi.org/10.1124/dmd.106.009530
[15]
Fuchikami, H., Satoh, H., Tsujimoto, M., et al. (2006) Effects of Herbal Extracts on the Function of Human Organic Anion-Transporting Polypeptide OATP-B. Drug Metabolism and Disposition, 34, 577-582. https://doi.org/10.1124/dmd.105.007872
